Status:
RECRUITING
Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLC
Lead Sponsor:
University Hospital, Brest
Conditions:
Advanced Non Small Cell Lung Cancer
Eligibility:
All Genders
Brief Summary
Therapeutic antibodies that block the programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) pathway have revolutionized immuno-oncology by inducing robust and durable responses in patients with ...
Eligibility Criteria
Inclusion
- Adult patients
- Advanced NSCLC with PD-L1 TPS of 50% or greater
- Administration of first line pembrolizumab between January 2017 \& December 2019
Exclusion
- Auto-immune disease
- Prior exposure to immunotherapy
- First dose pembrolizumab administered after December 2019
Key Trial Info
Start Date :
April 16 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 16 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04886401
Start Date
April 16 2021
End Date
May 16 2025
Last Update
February 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Brest
Brest, France, 29609